COMPASS THERAPEUTICS INC

CMPX is the ticker symbol for Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company. The stock represents an ownership stake in the company and trades on the Nasdaq Capital Market. CMPX focuses on developing antibody-based therapeutics for cancer and other diseases. As a stock, its value reflects investor expectations about the company's pipeline, trial outcomes, and financial position.

CMPX stock performance can vary widely based on clinical trial updates, financing news, and broader biotech market trends. For the most recent price changes and performance data, please refer to the live chart and performance metrics on this CMPX page. Historical returns are not a reliable indicator of future results, especially for clinical-stage companies.

Because CMPX is a clinical-stage biopharmaceutical company with no approved products, traditional valuation metrics like P/E ratios are often not meaningful. Investors typically assess valuation by examining cash reserves, pipeline potential, clinical trial progress, and comparable company analyses. For current market-based valuation figures such as market cap or enterprise value, please check the latest data on this CMPX page.

CMPX stock may be traded in pre-market and after-hours sessions through certain brokers, though liquidity is often lower and spreads can be wider than during regular market hours. Trading outside regular hours carries additional risks, such as reduced volume and greater price volatility. Investors should verify their broker's extended-hours policies and check the latest CMPX quote before placing orders.

Compass Therapeutics (CMPX) does not currently pay dividends. As a clinical-stage biopharmaceutical company, it typically reinvests any available capital into research and development rather than returning cash to shareholders. Dividend policies can change over time, so investors should review the company's latest financial statements and press releases for any updates.

Key risks for CMPX include clinical trial failures, regulatory delays, competition, and the need for additional financing to fund operations. As a clinical-stage company, it may not achieve profitability, and its stock price can be highly volatile. Broader market, economic, and interest rate changes can also affect CMPX. Reviewing SEC filings and the latest news is essential for a full risk assessment.